Today: 2 July 2026
Browse Category

NASDAQ:REGN 24 September 2025 - 19 May 2026

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron Pharmaceuticals shares lost 9.8% Monday. The company’s late-stage melanoma drug trial missed its main goal, putting new pressure on a pipeline that investors have seen as a key growth driver. Regeneron Pharmaceuticals Inc. closed at $629.68. Shares started at $615.93 and dropped to $610.60 at the session low, LSEG data on the company’s investor site showed. The stock trailed both the main market and other biotech names.
19 May 2026
·
Regeneron Opens Lower After Cancer Trial Setback

Regeneron Opens Lower After Cancer Trial Setback

Regeneron Pharmaceuticals shares dropped 11.8% in premarket trading Monday after its late-stage melanoma drug combo failed to meet its main goal. The move drew notice as Nasdaq futures pointed lower. Reuters singled out the decline before the bell, as premarket trading often moves on thin volume. Regeneron shares dropped after a trial that investors had counted on to showcase the cancer pipeline’s growth potential came up short. Investors are already watching for signs of strain on Eylea and continue to eye Dupixent, Regeneron’s partnership with Sanofi, for signs of future growth.
18 May 2026
··
Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Pharmaceuticals caught Wall Street’s attention again—investors now have more to chew on after a U.S. drug-pricing agreement, a unique FDA approval, and new backing from analysts, all ahead of next week’s earnings report. Timing is key here. Regeneron’s first-quarter numbers are set for release April 29, before U.S. markets open, and that recent jump in the stock has only intensified what’s already been a prominent debate in recent analyst notes: can the pipeline and potential policy tailwinds keep fueling gains after the last six months’ rally?
24 April 2026
··
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals, Inc. is ending 2025 in full “complex biotech” mode: the share price has rebounded, the dividend is now real, a flagship drug just got a powerful new label, a rare-disease medicine crushed a Phase 3 trial, and Wall Street is suddenly a bit less euphoric about the stock. On December 3, Morgan Stanley cut Regeneron from Overweight to Equal Weight with a $767 price target, arguing that the shares now more or less reflect fair value and that future upside will depend on how clearly the company can execute on its pipeline. MarketScreener+1
3 December 2025
··
Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Regeneron Stock Rockets on Strong Q3, Dupixent Boom – Analysts See 27% Upside

Key points: Regeneron shares recently traded around $580–$585 after a slight pullback earlier in the month investing.com. Over the past week REGN is up roughly 1–2%, recovering from a low in the high $570s investing.com. In its Oct. 28 earnings release, Regeneron reported Q3 2025 revenue of $3.75 billion, led by a 27% jump in Dupixent to $4.86 billion stocktitan.net. The company also won FDA approval for Libtayo in a high-risk skin cancer indication, and positive EU reviews for Libtayo and Dupixent stocktitan.net. Wall Street analysts have largely “buy” ratings on REGN: the consensus price target is about $725, implying ~25–27% upside tikr.com. The broader biotech sector has been rallying – for example, biotech ETFs are 25–34% higher since spring genengnews.com, outpacing the 24% gain in the S&P 500 over that span genengnews.com. Regeneron is still down from its 2024 highs, but recent drug wins and solid earnings are fueling renewed investor optimism. Regeneron shares have been trading in a $576–$585 range over the past week. For example, REGN closed at $575.69 on Oct. 23 and then rebounded to $585.31 by Oct. 27 investing.com. That roughly 1.7% lift reflects modest confidence among investors after a mid-October dip. Year-to-date REGN is
28 October 2025
···

Stock Market Today

  • Nabtesco (TSE:6268) beats profit estimates but valuation stays high
    July 2, 2026, 12:20 AM EDT. Nabtesco (TSE:6268) posted EPS 16.54% ahead of estimates, sending shares up 2.13% over 24 hours. The stock has climbed 30.53% in 90 days and returned 109.53% for shareholders over a year, though it pulled back 3.47% recently. Despite trading above the analyst consensus, Nabtesco sits 10.07% under one estimate of intrinsic value. Shares change hands at 38.1x earnings, far above the sector's 14.7x average, raising valuation risk if sentiment sours. The company faces headwinds from reshoring weighing on export volumes for motion control parts. Its push into new segments and focus on margins could help. The mix of strong gains and a stretched multiple presents a key choice for investors looking at robotics and automation stocks.
Go toTop